Harpoon Therapeutics Announces Updated Interim Tolerability

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete...

Related Keywords

Noura Choudhury ,Luke Walker ,Memorial Sloan Kettering Cancer Center ,Nasdaq ,Exchange Commission ,European Society Of Medical Oncology Congress ,Harpoon Therapeutics Inc ,Drug Administration ,European Society ,Medical Oncology Congress ,Activating Construct ,Principal Investigator ,Chief Medical Officer ,Orphan Drug Designation ,Harpoon Therapeutics ,Private Securities Litigation Reform Act ,Harpoon Therapeutic ,Nasdaq Harp ,